Lucid Diagnostics (LUCD) Share-based Compensation (2020 - 2026)

Lucid Diagnostics has reported Share-based Compensation for 7 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 36.99% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 7.34% YoY), and the FY2025 full-year result was $4.5 million, down 0.95% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.4 million, up from $1.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $3.8 million in Q2 2022, with the low at -$97000.0 in Q4 2023.
• Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 102.78% — and 2024, when it jumped 1307.22%.
• Lucid Diagnostics' Share-based Compensation stood at $3.5 million in 2022, then plunged by 102.78% to -$97000.0 in 2023, then jumped by 1307.22% to $1.2 million in 2024, then rose by 7.94% to $1.3 million in 2025, then climbed by 11.63% to $1.4 million in 2026.
• The last three Share-based Compensation figures came in at $1.4 million (Q1 2026), $1.3 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.